Literature DB >> 31287613

Diagnostic accuracy of 68 Ga-prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) and multiparametric (mp)MRI to detect intermediate-grade intra-prostatic prostate cancer using whole-mount pathology: impact of the addition of 68 Ga-PSMA PET to mpMRI.

Matthijs J Scheltema1,2,3, John I Chang1,2, Phillip D Stricker1,2, Pim J van Leeuwen1,2,4, Quoc A Nguyen1, Bao Ho5, Warick Delprado6, Jonathan Lee5, James E Thompson1,2, Thomas Cusick1, Alette S Spriensma3, Amila R Siriwardana1,2, Carlo Yuen7, Raji Kooner7, George Hruby8, Gordon O'Neill7, Louise Emmett1,5.   

Abstract

OBJECTIVE: To evaluate the ability of prostate-specific membrane antigen (PSMA)-positron-emission tomography (PET)/computed tomography (CT) to detect intermediate-grade intra-prostatic prostate cancer (PCa), and to determine if PSMA-PET improves the diagnostic accuracy of multiparametric magnetic resonance imaging (mpMRI). PATIENTS AND METHODS: A total of 56 consecutive patients with International Society of Urological Pathology (ISUP) grade 2-3 PCa after radical prostatectomy, who underwent both mpMRI and PSMA-PET CT (hereafter PSMA-PET) preoperatively, were enrolled in this study. The accuracy of PSMA-PET, mpMRI alone, and the two procedures in combination was analysed for identifying ISUP grades 1-3 within a 12-segment model. The accuracy of a combined predictive model (PSMA-PET and mpMRI) was determined. Receiver-operating characteristic curve analysis to determine the optimal standardized uptake value (SUVmax ) for PSMA-PET in discriminating between ISUP grades 1 and ≥2 was performed.
RESULTS: On a per-patient basis, the sensitivities for PSMA-PET and mpMRI in identifying ISUP grades 2-3 PCa were 100% and 97%, respectively. Assessing ISUP grade ≥2 PCa using a 12-segment analysis, PSMA-PET demonstrated greater diagnostic accuracy (area under the curve), sensitivity, specificity, negative predictive value (NPV) and positive predictive value (PPV), with values of 0.91, 88%, 93%, 95% and 85%, respectively, than did mpMRI (Prostate Imaging Reporting and Data System [PI-RADS] 3-5), at 0.79, 68%, 91%, 87%, and 75%, respectively. When used in combination (PSMA-PET and mpMRI PIRADS 4-5), sensitivity, specificity, NPV and PPV were 92%, 90%, 96% and 81%, respectively. The sensitivity for both techniques reduced markedly when assessing ISUP grade 1 PCa (18% for PSMA-PET, 10% for mpMRI). An SUVmax value of 3.95 resulted in 94% sensitivity and 100% specificity.
CONCLUSION: PSMA-PET is accurate in detecting segments containing intermediate-grade intra-prostatic PCa (ISUP grade ≥ 2), compared with and complementary to mpMRI. By contrast the detection rate for ISUP grade 1 disease for both PSMA-PET and mpMRI was low.
© 2019 The Authors BJU International © 2019 BJU International Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990PSMAzzm321990; #PCSM; #ProstateCancer; PET-CT; diagnostic imaging; mpMRI; prostate cancer

Mesh:

Substances:

Year:  2019        PMID: 31287613     DOI: 10.1111/bju.14794

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  11 in total

1.  Dual-tracer PET/CT-targeted, mpMRI-targeted, systematic biopsy, and combined biopsy for the diagnosis of prostate cancer: a pilot study.

Authors:  Dong-Xu Qiu; Jian Li; Jin-Wei Zhang; Min-Feng Chen; Xiao-Mei Gao; Yong-Xiang Tang; Ye Zhang; Xiao-Ping Yi; Hong-Ling Yin; Yu Gan; Gui-Lin Wang; Xiong-Bing Zu; Shuo Hu; Yi Cai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-12-03       Impact factor: 10.057

2.  Single-fraction image-guided robotic radiosurgery efficiently controls local prostate cancer recurrence after radical prostatectomy.

Authors:  A Spek; A Graser; G Habl; A Muacevic; C Fuerweger; M Seitz; A Haidenberger
Journal:  BJUI Compass       Date:  2020-08-05

3.  Canadian Urological Association best practice report: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and PET/magnetic resonance (MR) in prostate cancer.

Authors:  Bobby Shaygan; Katherine Zukotynski; François Bénard; Cynthia Ménard; Joda Kuk; Golmehr Sistani; Glenn Bauman; Patrick Veit-Haibach; Ur Metser
Journal:  Can Urol Assoc J       Date:  2021-06       Impact factor: 1.862

4.  Comparison of 68Ga-PSMA-617 PET/CT with mpMRI for the detection of PCa in patients with a PSA level of 4-20 ng/ml before the initial biopsy.

Authors:  Yu Li; Donghui Han; Peng Wu; Jing Ren; Shuaijun Ma; Jingliang Zhang; Wei Song; Xiaoyu Lin; Dian Jiao; Shengjia Shi; Fa Yang; Jieheng Wu; Ping Meng; Weihong Wen; Fei Kang; Jing Wang; Weijun Qin
Journal:  Sci Rep       Date:  2020-07-03       Impact factor: 4.379

5.  Detection of prostate cancer with 18F-DCFPyL PET/CT compared to final histopathology of radical prostatectomy specimens: is PSMA-targeted biopsy feasible? The DeTeCT trial.

Authors:  Y J L Bodar; B H E Jansen; J P van der Voorn; G J C Zwezerijnen; D Meijer; J A Nieuwenhuijzen; R Boellaard; N H Hendrikse; O S Hoekstra; R J A van Moorselaar; D E Oprea-Lager; A N Vis
Journal:  World J Urol       Date:  2020-10-20       Impact factor: 4.226

6.  SUVmax/ADC Ratio as a Molecular Imaging Biomarker for Diagnosis of Biopsy-Naïve Primary Prostate Cancer.

Authors:  Sheela Chinnappan; Piyush Chandra; John Santa Kumar; Ganesan Chandran; Satish Nath
Journal:  Indian J Nucl Med       Date:  2021-12-15

Review 7.  Comparison of Multiparametric Magnetic Resonance Imaging with Prostate-Specific Membrane Antigen Positron-Emission Tomography Imaging in Primary Prostate Cancer Diagnosis: A Systematic Review and Meta-Analysis.

Authors:  Yi Zhao; Benjamin S Simpson; Naomi Morka; Alex Freeman; Alex Kirkham; Daniel Kelly; Hayley C Whitaker; Mark Emberton; Joseph M Norris
Journal:  Cancers (Basel)       Date:  2022-07-19       Impact factor: 6.575

8.  PEDAL protocol: a prospective single-arm paired comparison of multiparametric MRI and 18F-DCPFyl PSMA PET/CT to diagnose prostate cancer.

Authors:  Vy Tran; Anne Hong; Tom Sutherland; Kim Taubman; Su-Faye Lee; Daniel Lenaghan; Kapil Sethi; Niall M Corcoran; Nathan Lawrentschuk; H Woo; Lisa Tarlinton; Damien Bolton; Tim Spelman; Lauren Thomas; Russell Booth; Justin Hegarty; Elisa Perry; Lih-Ming Wong
Journal:  BMJ Open       Date:  2022-09-19       Impact factor: 3.006

9.  Influence of Urethra Sparing on Tumor Control Probability and Normal Tissue Complication Probability in Focal Dose Escalated Hypofractionated Radiotherapy: A Planning Study Based on Histopathology Reference.

Authors:  Simon K B Spohn; Ilias Sachpazidis; Rolf Wiehle; Benedikt Thomann; August Sigle; Peter Bronsert; Juri Ruf; Matthias Benndorf; Nils H Nicolay; Tanja Sprave; Anca L Grosu; Dimos Baltas; Constantinos Zamboglou
Journal:  Front Oncol       Date:  2021-05-14       Impact factor: 6.244

10.  Establishment and prospective validation of an SUVmax cutoff value to discriminate clinically significant prostate cancer from benign prostate diseases in patients with suspected prostate cancer by 68Ga-PSMA PET/CT: a real-world study.

Authors:  Jianhua Jiao; Fei Kang; Jingliang Zhang; Zhiyong Quan; Weihong Wen; Xiaohu Zhao; Shuaijun Ma; Peng Wu; Fa Yang; Wei Guo; Xiaojian Yang; Jianlin Yuan; Yongquan Shi; Jing Wang; Weijun Qin
Journal:  Theranostics       Date:  2021-07-25       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.